This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

0NQA Stock Overview

Elanix Biotechnologies AG, a tissue regeneration company, engages in the development and commercialization of products for acute wound care. More details

0NQA fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Shares are highly illiquid

Latest financial reports are more than a year old

Does not have a meaningful market cap (€687K)

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Elanix Biotechnologies AG Competitors

ReNeuron Group

AIM:RENE

UK£1.9m

Aptamer Group

AIM:APTA

UK£7.4m

Theracryf

AIM:TCF

UK£5.0m

Genflow Biosciences

LSE:GENF

UK£3.5m

Price History & Performance

Summary of share price highs, lows and changes for Elanix Biotechnologies
Historical stock prices
Current Share Price	€0.07
52 Week High	€0.07
52 Week Low	€0.07
Beta	0
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	-96.41%
Change since IPO	-98.77%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	0NQA	GB Biotechs	GB Market
7D	0%	2.1%	-0.3%
1Y	n/a	-13.2%	-0.4%

Return vs Industry: Insufficient data to determine how 0NQA performed against the UK Biotechs industry.

Return vs Market: Insufficient data to determine how 0NQA performed against the UK Market.

Price Volatility

Is 0NQA's price volatile compared to industry and market?
0NQA volatility
0NQA Average Weekly Movement	n/a
Biotechs Industry Average Movement	8.9%
Market Average Movement	5.8%
10% most volatile stocks in GB Market	11.1%
10% least volatile stocks in GB Market	3.2%

Stable Share Price: 0NQA has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine 0NQA's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
n/a	n/a	Lee-Ann Laurent-Applegate	www.elanixbiotechnologies.ch

Elanix Biotechnologies AG, a tissue regeneration company, engages in the development and commercialization of products for acute wound care. The company is based in Frankfurt am Main, Germany.

Elanix Biotechnologies AG Fundamentals Summary

How do Elanix Biotechnologies's earnings and revenue compare to its market cap?
0NQA fundamental statistics
Market cap	€686.88k
Earnings (TTM)	-€4.46m
Revenue (TTM)	€280.19k

0.0x

P/S Ratio

0.0x

P/E Ratio

Is 0NQA overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0NQA income statement (TTM)
Revenue	€280.19k
Cost of Revenue	€348.59k
Gross Profit	-€68.39k
Other Expenses	€4.39m
Earnings	-€4.46m

Last Reported Earnings

Jun 30, 2018

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did 0NQA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2023/03/12 05:42
End of Day Share Price	2022/12/13 00:00
Earnings	2018/06/30
Annual Earnings	2017/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Elanix Biotechnologies AG is covered by 1 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Brigitte de Lima	goetzpartners securities Limited